DaVita Inc. is a leading healthcare provider focused on transforming care delivery to improve the quality of life for patients globally. They are one of the largest providers of kidney care services in the U.S., caring for patients at every stage of their kidney health journey. DaVita is committed to patient-centric care models, implementing the latest technologies, and advancing integrated care offerings. The company has established a value-based culture focused on both patients and teammates.

• Employees: Approximately 70,000 (as of December 31, 2023)
• Geographic Footprint: 11 countries outside of the U.S.
• Headquarters: Denver, CO
• Founded: 1994 (initial public offering)
• Number of locations/facilities: 2,675 outpatient dialysis centers in the U.S. and 367 outpatient dialysis centers internationally (as of December 31, 2023)
• Revenue: $12.14 billion (FY2023)
• Market Cap: Approximately $9.2 billion (as of June 30, 2023)
• Key Subsidiaries/Brands: DaVita Integrated Kidney Care (DaVita IKC), Nephrology Practice Solutions (NPS), DaVita Clinical Research (DCR), MedSleuth, DaVita Venture Group (DVG)

• CEO: Javier J. Rodriguez
• CFO: Joel Ackerman
• Chief Accounting Officer: Christopher M. Berry
• Board Chair: Pamela M. Arway

Key executives have extensive experience in healthcare and finance. The Board is composed of 40% women and 10% people of color.

• Annual Revenue: $12.14 billion (FY2023)
• Net Income: $691.5 million
• Market Cap: Approximately $9.2 billion (as of June 30, 2023)
• Total Assets: $16.89 billion
• Employees: Approximately 70,000 (as of December 31, 2023)
• Key Financial Highlights: U.S. dialysis revenue growth of 3.2%, IKC revenue growth of 35.2% and international revenue growth of 9.0% (FY2023)

DaVita provides a range of kidney care services, including:

• U.S. Dialysis Services: Outpatient hemodialysis, hospital inpatient hemodialysis, home-based dialysis, and related lab services.
• U.S. Integrated Kidney Care (IKC): Integrated care and disease management services for patients with CKD and ESKD.
• Other Ancillary Services: Clinical research, transplant software, and venture investments.
• International Dialysis: Dialysis and administrative services in 11 countries outside the U.S.

DaVita operates through the following key business segments:

• U.S. Dialysis: Provides dialysis and related lab services in the U.S.
• Other - Ancillary Services: Includes U.S. integrated kidney care, U.S. other ancillary services and international operations.

DaVita's strategy focuses on integrated care, value-based care models, and home-based dialysis. Key strategic initiatives include:

• Expanding integrated care capabilities to coordinate care across the renal care continuum.
• Implementing value-based payment models to improve clinical outcomes and reduce costs.
• Increasing the use of home dialysis and kidney transplants.
• Investing in innovative technologies and digital health solutions.

The company is also focused on maintaining a strong value-based culture and improving clinical outcomes.

DaVita operates in the highly competitive kidney care industry. Key market trends include:

• Primary Industry: Kidney care and dialysis services.
• Market Trends: Increasing prevalence of chronic kidney disease, growing adoption of value-based care, and a shift towards home-based dialysis.
• Key Competitors: Fresenius Medical Care (FMC) is a major competitor, along with other large and medium-sized dialysis providers, individual nephrologists, and new entrants in the integrated care space.
• Market Position: DaVita is one of the two largest dialysis providers in the U.S. with an estimated 36% market share.

• Operational Risks: Labor shortages, supply chain disruptions, and the ability to maintain and upgrade information systems.
• Regulatory Risks: Changes in healthcare laws and regulations, including Medicare and Medicaid payment policies, and compliance with complex privacy and security laws.
• Financial Risks: Uncertainty about future payment rates, changes in commercial insurance coverage, and potential impacts of economic conditions on the business.
• Competitive Risks: Intense competition from other dialysis providers and new entrants in the integrated care space, as well as the ability to retain patients and physicians.
• Legal Risks: Potential lawsuits, demands, claims, qui tam suits, governmental investigations and audits and other legal matters.